The emergence of retatrutide as a triple hormone receptor agonist has fundamentally changed how researchers think about metabolic disease. Where semaglutide targets a single receptor and tirzepatide two, retatrutide simultaneously activates GLP-1, GIP, and glucagon receptors — producing effects that go well beyond simple appetite suppression.
Semaglutide, approved under the brand names Ozempic and Wegovy, operates as a selective GLP-1 receptor agonist. Its mechanism is well understood: it slows gastric emptying, reduces appetite through central nervous system signalling, and improves insulin secretion in a glucose-dependent manner. STEP trial data showed a mean weight reduction of 14.9% at 68 weeks — impressive by historical standards, but now eclipsed by newer compounds.
Tirzepatide, a dual GIP/GLP-1 agonist, added GIP receptor agonism to the equation. The addition of GIP activity appears to enhance insulin sensitisation beyond what GLP-1 alone can achieve, and SURMOUNT-1 trial data demonstrated a mean weight reduction of 22.5% at 72 weeks at the 15mg dose — a substantial improvement over semaglutide monotherapy.
Retatrutide goes one step further, adding glucagon receptor agonism to the GLP-1/GIP combination. Glucagon receptor activation increases energy expenditure through thermogenic mechanisms, adds direct hepatic fat reduction, and provides additional appetite suppression through independent pathways. Phase 2 data showed mean weight reduction of up to 24.2% at 48 weeks — and crucially, the weight loss trajectory had not plateaued by week 48, suggesting even greater reduction with longer treatment duration.
The addition of glucagon receptor agonism is the most pharmacologically interesting element of retatrutide's profile. Glucagon was historically considered undesirable in metabolic therapy — it raises blood glucose and was associated with hyperglycaemia. However, researchers have demonstrated that when glucagon receptor agonism is balanced with sufficient GLP-1 receptor activity, the glucose-raising effect of glucagon is neutralised while its metabolically beneficial effects are preserved.
These beneficial glucagon effects include: increased hepatic fat oxidation, direct stimulation of energy expenditure in brown adipose tissue, and suppression of appetite through distinct neural pathways from those activated by GLP-1. The net result is a compound that burns more fat and expends more energy than a dual agonist, without the glycaemic side effects historically associated with glucagon.
One of the most striking findings from retatrutide Phase 2 data was its effect on hepatic fat content. Participants showed dramatic reductions in liver fat fraction — a clinically significant finding given the growing recognition of metabolic-associated steatotic liver disease (MASLD) as a major comorbidity of obesity. The glucagon receptor component is believed to be primarily responsible for this hepatic benefit, as glucagon directly stimulates hepatic fatty acid oxidation and reduces lipid synthesis in the liver.
Tirzepatide also shows hepatic benefits through its GIP component, but retatrutide's triple mechanism produces additive hepatic effects that neither dual nor single agonist can replicate.
For researchers designing metabolic studies, the choice between these three compounds depends on the specific endpoints being investigated. Semaglutide remains the gold standard reference compound with the most robust long-term safety and efficacy data. Tirzepatide is ideal for studying the additive effects of GIP agonism on insulin sensitisation and lipid metabolism. Retatrutide opens entirely new research territory around thermogenesis, energy expenditure, and the glucagon receptor's role in obesity.
All three compounds from SyntheticLabs are supplied at research-grade purity with full CoA documentation, making them suitable for comparative in vitro and preclinical research across all three mechanisms.